RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Semaglutide for Cardiovascular Risk

Q: Is NCT07900438 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07900438?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07900438?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

The purpose of this clinical study is to find out what happens to kidney and heart health during treatment with a medicine called semaglutide, which is given as an injection under the skin. The clinical study will also look at whether this medicine is safe for adults who have type 2 diabetes (T2D) and chronic kidney disease (CKD).

Official registry: https://clinicaltrials.gov/study/NCT07900438 · Novo Nordisk A/S · enrollment listed as 300

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Semaglutide. The registry lists allocation as na. The purpose of this clinical study is to find out what happens to kidney and heart health during treatment with a medicine called semaglutide, which is given as an injection under the skin.

They plan to enroll about 300 people at 26 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

Interventions: Semaglutide

Primary outcome (registry wording): Time to first occurrence of a composite endpoint consisting of: Onset of persistent reduction of ≥ 50% in eGFR compared with baseline, Onset of persistent eGFR < 15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death, CV death

Who it is for (from inclusion criteria)

Ages 18 Years to any
Diagnosed with type 2 diabetes (T2D)
HbA1c less than or equal to (≤) 10 % (≤ 86 millimoles per mole \[mmol/mol\])
Kidney impairment defined either by:
serum creatinine-based eGFR greater than or equal to (≥) 50 and less than or equal to (≤) 75 mL/min/1.73 m\^2 (CKD-EPI, 2009) and UACR greater than (\>) 300 and less than (\<) 5000 milligrams per gram (mg/g) or
serum creatinine-based eGFR ≥ 25 and \< 50 mL/min/1.73 m\^2 (CKD-EPI, 2009) and UACR \> 100 and \< 5000 mg/g
Laboratory results for inclusion can be based on:
measurements no more than 90 days old at screening, documented in medical records or

Who the registry excludes

Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations
Use of any glucagon-like peptide-1 receptor agonist (GLP1 RA) within 30 days prior to screening. This also includes dual agonists containing a GLP1 RA component
Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 60 days prior to the day of screening
Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis
Combination use of an angiotensin-converting enzyme inhibitor and an angiotensin-II receptor blocker (ARB)

Public study contact (from the registry)

Novo Nordisk

(+1) 866-867-7178

clinicaltrials@novonordisk.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

26 listed

Fu Yang People's Hospital-Nephrology — Fuyang, Anhui, China (not_yet_recruiting)
Beijing Anzhen Hospital, Capital Medical University-Nephrology — Beijing, Beijing Municipality, China (recruiting)
Peking University First Hospital-Nephrology — Beijing, Beijing Municipality, China (not_yet_recruiting)
Beijing Friendship Hospital, Capital Medical University-Nephrology — Beijing, Beijing Municipality, China (not_yet_recruiting)
The Second Hospital & Clinical Medical School, Lanzhou University-Nephrology — Lanzhou, Gansu, China (not_yet_recruiting)
Huizhou Central People's Hospital-Endocrinology — Huizhou, Guangdong, China (not_yet_recruiting)
The Second Affiliated Hospital of Shantou University Medical College-Nephrology — Shantou, Guangdong, China (not_yet_recruiting)
The Second Hospital of Hebei Medical University-Nephrology — Shijiazhuang, Hebei, China (not_yet_recruiting)
The People's Hospital of Anyang City/ TGE Center Hospital of Anyang City-Nephrology — Anyang, Henan, China (not_yet_recruiting)
Yichang Central People's Hospital-Nephrology — Yichang, Hubei, China (not_yet_recruiting)
The First Affiliated Hospital of Baotou Medical College-Nephrology — Baotou, Inner Mongolia, China (not_yet_recruiting)
Changzhou No.2 People's Hospital-Nephrology — Changzhou, Jiangsu, China (not_yet_recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07900438 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07900438?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07900438?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary